Clinical update on bivalent COVID-19 booster platform.
Moderna, Inc., announced new clinical data on its bivalent COVID-19 booster platform including data on the Company's first bivalent booster candidate, mRNA-1273.211, which includes mutations found in the Beta variant of concern, several of which have been persistent in more recent variants of concern including Omicron.
A50 µg booster dose ofmRNA-1273.211 demonstrated superiority against Beta, Delta and Omicron variants of concern one month after administration. Superiority continued six months after administration for Beta and Omicron variants of concern as well. A50 µg booster dose of mRNA-1273.211 was generally well tolerated with a reactogenicity profile comparable to a booster dose of mRNA-1273 at the 50 µg dose level.
See- Research Square: "Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine":Spyros Chalkias, Frank Eder, Brandon Essink, Shishir Khetan, Biliana Nestorova, and 13 more.https://doi.org/10.21203/rs.3.rs-1555201/v1.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.